This observational study aims to identify biomarkers and cellular factors that influence the efficacy and durability of CAR-T therapies in patients with hematologic malignancies. With an estimated enrollment of 700 patients, the findings could significantly enhance patient selection and treatment personalization, potentially leading to improved response rates and reduced relapse. The study's outcomes may provide valuable insights for pharmaceutical companies developing next-generation CAR-T therapies, positioning them competitively in a rapidly evolving market. The focus on durable responses aligns with industry trends towards personalized medicine, making this research critical for stakeholders in the CAR-T space.